title: Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy.
abstract: BACKGROUND
  Mucinous, medullary, and tubular carcinomas are uncommon types of breast cancer whose rarity does not permit large single-institution studies or randomized trials to define optimal treatments. In this study, we evaluated the long-term outcomes of breast-conserving therapy (BCT) for these subtypes of breast cancer and compared them with those for invasive ductal carcinoma.
  
  
  METHODS
  In our institutional database of patients who received BCT from 1965 to 1999, 1,643 patients with stage I to II mucinous (61), medullary (37), tubular (60), and invasive ductal (1,485) histologies were identified. The clinical and pathologic features of the 4 groups were evaluated and compared with respect to local-regional recurrence rates, disease-free survival, and overall survival (OS).
  
  
  RESULTS
  No statistically significant differences were found in the local-regional failure rate among the 4 groups (10.6-year median follow-up). Only patients with tubular carcinoma had better 5- and 10-year OS rates (P = .013). In multivariable analysis, factors associated with improved OS included age at or below 50 years, negative nodal status, use of chemotherapy or hormonal therapy, and tubular histology.
  
  
  CONCLUSIONS
  BCT for mucinous, medullary, or tubular carcinoma resulted in similar local-regional failure rates to that for invasive ductal carcinoma. Tubular carcinoma patients had the most favorable OS. BCT is an appropriate treatment strategy for early-stage mucinous, medullary, and tubular carcinomas.
authors.affiliation: Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
authors.forename: Thao
authors.initials: T
authors.lastname: Vo
authors.forename: Yan
authors.initials: Y
authors.lastname: Xing
authors.forename: Funda
authors.initials: F
authors.lastname: Meric-Bernstam
authors.forename: Nadeem
authors.initials: N
authors.lastname: Mirza
authors.forename: Georges
authors.initials: G
authors.lastname: Vlastos
authors.forename: W Fraser
authors.initials: WF
authors.lastname: Symmans
authors.forename: George H
authors.initials: GH
authors.lastname: Perkins
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Buchholz
authors.forename: Gildy V
authors.initials: GV
authors.lastname: Babiera
authors.forename: Henry M
authors.initials: HM
authors.lastname: Kuerer
authors.forename: Isabelle
authors.initials: I
authors.lastname: Bedrosian
authors.forename: Jeri S
authors.initials: JS
authors.lastname: Akins
authors.forename: Kelly K
authors.initials: KK
authors.lastname: Hunt
mesh_terms: D000230:Adenocarcinoma / Q000601:surgery*; D002288:Adenocarcinoma, Mucinous / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000601:surgery*; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome